Biologics and allergy drops for dust mite asthma
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests combining a biologic drug (omalizumab) with allergy drops (sublingual immunotherapy) to see if they work better together for people with moderate asthma triggered by dust mites. It may help control your asthma symptoms better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have moderate asthma that is partly controlled and caused by dust mites.
- Your total IgE level is between 30 and 700 IU/mL.
- You have a positive skin test for dust mites (D. pteronyssinus or D. farinae).
- Your lung function (FEV1) is above 70% of normal.
- You have not had allergy shots or drops in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether dust-mite allergy treatment (likely allergy shots) can reduce allergy symptoms and improve safety. It focuses on people whose nose/eye allergy is triggered by house dust mites and who may also have controlled asthma.
This trial tests if omalizumab, an allergy medication, can help people with COPD who have allergies to common indoor triggers like cat, dog, mouse, cockroach, or dust mite. It aims to reduce flare-ups and improve breathing.
This trial tests allergy drops placed under the tongue to treat allergic rhinitis caused by house dust mites. It aims to see if the drops can safely reduce symptoms like sneezing and stuffy nose.
This trial tests a dust-mite allergy extract (“allergy shots”) to see if it safely reduces symptoms from dust-mite–driven hay fever (rhinitis/rhinoconjunctivitis), and possibly asthma symptoms. If you qualify, it may help your immune system tolerate dust mites better over time.
This trial tests an under-the-tongue tablet for people with dust mite allergies causing moderate to severe nasal symptoms or mild-to-moderate asthma. The goal is to see if it improves symptoms and can replace or reduce the need for allergy medicines.
This trial tests if omalizumab (a drug that blocks allergy reactions) can help people with multiple food allergies. You might qualify if you have severe allergies to at least two foods like peanut, tree nuts, egg, or milk.
Hear when a new Asthma, Allergic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.